NATURAL ALTERNATIVES INTERNATIONAL, INC.

Natural Alternatives International, Inc.

NAII

US6388423021

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:30:01 04/06/2024 BST			5-day change	1st Jan Change
6.5 ^USD	-1.81%		-0.76%	-0.46%

05-14	Earnings Flash (NAII) NATURAL ALTERNATIVES INTERNATIONAL Posts Q3 Revenue $25.1M	MT
05-14	Natural Alternatives International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI

Natural Alternatives International, Inc. Appoints Nicole Burbank as Vice President of CarnoSyn Brands

September 18, 2018 at 08:01 pm

Natural Alternatives International, Inc. announced and welcome Nicole Burbank as Vice President of CarnoSyn Brands. Nicole will be responsible for the leadership of the CarnoSyn business teams and the advancement of new and existing business opportunities, including the expansion of SR CarnoSyn beta-alanine into the general wellness and healthy aging categories.

Latest news about Natural Alternatives International, Inc.

Earnings Flash (NAII) NATURAL ALTERNATIVES INTERNATIONAL Posts Q3 Revenue $25.1M	05-14	MT
Natural Alternatives International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	05-14	CI
Natural Alternatives International Scheduled to Reopen U.S. Manufacturing Facility in California to Support Increased Production Needs	04-02	CI
CarnoSyn®? Brands Partners with Barentz for Exclusive Brazilian Distribution of CarnoSyn®? Beta-Alanine	02-15	CI
Earnings Flash (NAII) NATURAL ALTERNATIVES INTERNATIONAL Reports Q2 Revenue $25.2M	02-13	MT
Earnings Flash (NAII) NATURAL ALTERNATIVES INTERNATIONAL Reports Q1 Revenue $34M	11-09	MT
Tranche Update on Natural Alternatives International, Inc.'s Equity Buyback Plan announced on June 3, 2011.	11-09	CI
Natural Alternatives International, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-09	CI
North American Morning Briefing : Yield Surge -2-	26/09/23	DJ
Earnings Flash (NAII) NATURAL ALTERNATIVES INTERNATIONAL Reports Q4 Revenue $35.9M	21/09/23	MT
Tranche Update on Natural Alternatives International, Inc.'s Equity Buyback Plan announced on June 3, 2011.	21/09/23	CI
Natural Alternatives International, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	21/09/23	CI
North American Morning Briefing : Stock Futures -2-	19/09/23	DJ
Natural Alternatives Temporarily Shuts New Facility in California; Staff Furlough Notice Issued; Shares Drop After Hours	16/08/23	MT
Natural Alternatives International, Inc. Announces Temporary Plant Closure and Employee Furloughs	16/08/23	CI
Natural Alternatives International Appoints Shane Conti as New VP of Global Sales	25/07/23	CI
Natural Alternatives International, Inc. Enters into A Fourth Amendment to Lease Amending and Extending the Term of the Lease of Its Vista California Manufacturing Facilities	24/07/23	CI
Natural Alternatives International Adds New Manufacturing Unit in California	24/05/23	MT
Earnings Flash (NAII) NATURAL ALTERNATIVES INTERNATIONAL Reports Q3 Revenue $32.7M	15/05/23	MT
Tranche Update on Natural Alternatives International, Inc.'s Equity Buyback Plan announced on June 3, 2011.	15/05/23	CI
Natural Alternatives International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	15/05/23	CI
North American Morning Briefing : Hopes of Easing -2-	12/05/23	DJ
Earnings Flash (NAII) NATURAL ALTERNATIVES INTERNATIONAL Posts Q2 Revenue $42.3M	08/02/23	MT
Tranche Update on Natural Alternatives International, Inc.'s Equity Buyback Plan announced on June 3, 2011.	08/02/23	CI
Natural Alternatives International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	08/02/23	CI

Chart Natural Alternatives International, Inc.

Duration

Period

Chart Natural Alternatives International, Inc.

More charts

Company Profile

Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. The Company operates through two segments: Private-label contract manufacturing, and Royalty, licensing, and raw material. The Private-label contract manufacturing segment primarily provides manufacturing services to companies that market and distribute nutritional supplements and other health care products. Royalty, licensing, and raw material segment associated with the sale and license of beta-alanine under the Companyâs CarnoSyn and SR CarnoSyn trademarks. The Company provides private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal and other nutritional supplements as well as other health care products. It private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores.

Sector

Pharmaceuticals

Calendar

17/09/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NATURAL ALTERNATIVES INTERNATIONAL, INC.	-0.46%	40.31M
ELI LILLY AND COMPANY	+42.83%	750B
NOVO NORDISK A/S	+34.11%	606B
JOHNSON & JOHNSON	-5.70%	356B
MERCK & CO., INC.	+18.06%	326B
ABBVIE INC.	+4.63%	286B
ASTRAZENECA PLC	+18.36%	246B
ROCHE HOLDING AG	-2.86%	213B
NOVARTIS AG	+11.10%	213B
PFIZER, INC.	+2.43%	167B

Other Pharmaceuticals